Shots:
- AstraZeneca has selected a novel CKD target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter its portfolio
- In 2019, companies collaborated to discover new drugs for CKD and IPF
- The collaboration leverages AstraZeneca’s scientific expertise and rich datasets with BenevolentAI’s target identification platform to understand these two complex diseases’ underlying mechanisms and identify new drug targets
Click here to read full press release/ article | Ref: PRNewswire | Image: Express Journal
The post AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI first appeared on PharmaShots.
